Compounds > norquetiapine
Page last updated: 2024-11-12

norquetiapine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

norquetiapine: metabolite of quetiapine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11369918
CHEMBL ID3526391
CHEBI ID188278
SCHEMBL ID8311
MeSH IDM0574371

Synonyms (47)

Synonym
BB 0261035
5747-48-8
FT-0665928
CHEBI:188278
6-piperazin-1-ylbenzo[b][1,4]benzothiazepine
norquetiapine
A8192
11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine;11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine
A25082
dibenzo[b,f][1,4]thiazepine, 11-(1-piperazinyl)-
11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine
11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine
AKOS015854153
SCHEMBL8311
6-piperazin-1-ylbenzo[b][1,5]benzothiazepine
gtpl7545
JLOAJISUHPIQOX-UHFFFAOYSA-N
11-(piperazin-1-yl)-dibenzo[b,f][1,4]thiazepin
11-piperazinyldibenzo[b,f][1,4]thiazepine
11-piperazinyl-dibenzo[b,f][1,4]thiazepine
11piperazinyldibenzo[b,f][1,4]thiazepine
11-piperazinyldibenzo[b,f]-[1,4]-thiazepine
11-piperazin-1-yldibenzo[b,f][1,4]thiazepine
11-piperazin-1-yldibenzo[b,f][1,4]thiazepin
(e)-11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine
us8653257, 11-piperazin-1-yl-dibenzo[b,f][1,4]thiazepine
bdbm141313
CHEMBL3526391
unii-v3h1zvv9s6
quetiapine fumarate impurity b [ep impurity]
V3H1ZVV9S6 ,
norquetiapine, analytical standard
W17065
MRF-0000028
CS-0045376
11-piperazin-1-yl-dibenzo[b,f][1,4]thiazepine
SY096658
mfcd09835366
DS-15433
Q27078068
CCG-357082
BCP29749
n-des[2-(2-hydroxyethoxy)ethyl] quetiapine
AMY36467
DTXSID30881147
discontinued see: d288740
n-des[2-(2-hydroxyethoxy)ethyl]quetiapine

Research Excerpts

Effects

ExcerptReferenceRelevance
"Norquetiapine has a specific effect on anxiety and depressive symptoms, showing a correlation between plasma concentrations and clinical efficacy only in patients with bipolar depression."( Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study.
Altamura, AC; Bareggi, SR; Buoli, M; Dell'osso, B; Mauri, MC; Moliterno, D; Paletta, S, 2012)		1.4

Toxicity

ExcerptReferenceRelevance
" Adverse events, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests were evaluated throughout the studies."( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.
Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)		0.57
" Quetiapine was well tolerated, with no serious adverse events and no unexpected events reported."( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.
Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)		0.57

Dosage Studied

ExcerptRelevanceReference
" The predictability in quetiapine concentration profiles for children aged 10 years to adults suggests that no dosage adjustment may be required when treating patients of these ages."( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.
Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)		0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dibenzothiazepine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1220273Drug metabolism in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2C19 inhibitor benzylnirvanol2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220285Activity of cytochrome P450 in human liver microsomes by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220295Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as metabolite M3 formation after 60 mins by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220270Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2D6 inhibitor quinidine2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220274Drug metabolism in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2C9 inhibitor sulfaphenazole2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220275Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2C19 inhibitor benzylnirvanol2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220269Activity of human CYP3A4 expressed in xenosomes assessed as intrinsic clearance per pmol protein by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220267Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as N-desalkylquetiapine sulfoxide formation after 60 mins by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220290Activity of cytochrome P450 in human liver microsomes assessed as metabolite M3 formation by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220277Drug metabolism in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220272Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP1A2 inhibitor fluvoxamine2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220292Drug metabolism in human liver microsomes assessed as 1 uM CYP3A4 inhibitor ketoconazole-mediated inhibition of N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220294Drug metabolism in human liver microsomes assessed as CYP1A2 inhibitor fluvoxamine-mediated inhibition of 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220276Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP2C9 inhibitor sulfaphenazole2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220268Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as 7-hydroxy-N-desalkylquetiapine formation after 60 mins by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220286Activity of cytochrome P450 in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation measured as substrate inhibition constant by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220271Drug metabolism in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation at 3 uM after 30 mins by mass spectroscopy in presence of CYP3A4 inhibitor ketoconazole2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220296Activity of human CYP3A4 expressed in supersomes co-expressing cytochrome P450 reductase assessed as metabolite M3 formation after 60 mins by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220265Activity of human CYP3A4 expressed in supersomes co-expressing cytochrome P450 reductase assessed as N-desalkylquetiapine sulfoxide formation after 60 mins by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220284Activity of cytochrome P450 in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation measured as low-affinity/high-capacity binding constant by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220291Drug metabolism in human liver microsomes assessed as 5 uM CYP2D6 inhibitor quinidine-mediated inhibition of 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220262Activity of human CYP3A4 expressed in xenosomes assessed as substrate depletion after 60 mins by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220293Drug metabolism in human liver microsomes assessed as 1 uM CYP3A4 inhibitor ketoconazole-mediated inhibition of metabolite M3 formation at 3 uM after 30 mins by mass spectroscopy2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220264Drug metabolism in human liver microsomes assessed as 7-hydroxy-N-desalkylquetiapine formation at 3 uM after 30 mins by mass spectroscopy2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220263Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as substrate depletion after 60 mins by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220283Activity of cytochrome P450 in human liver microsomes assessed as N-desalkylquetiapine sulfoxide formation measured as high-affinity/low-capacity binding constant by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1220261Activity of human CYP2D6 expressed in supersomes co-expressing cytochrome P450 reductase assessed as intrinsic clearance per pmol protein by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
AID1346971Human NET (Monoamine transporter subfamily)2008Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Sep, Volume: 33, Issue:10
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (10.53)29.6817
2010's14 (73.68)24.3611
2020's3 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.63 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index5.54 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (15.79%)5.53%
Reviews1 (5.26%)6.00%
Case Studies1 (5.26%)4.05%
Observational0 (0.00%)0.25%
Other14 (73.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		2.17102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
quetiapine
[no description available]		2.0410dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
reboxetine
Reboxetine: A morpholine derivative that is a selective and potent noradrenaline reuptake inhibitor; it is used in the treatment of DEPRESSIVE DISORDER.		2.1710aromatic ether
raclopride
Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.		4.3711salicylamides
fluvoxamine
Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.		2.0710(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
neuropeptide y
Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.		3.4611
quetiapine fumarate
Quetiapine Fumarate: A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.		8.57163fumarate salt
ConditionIndicatedRelationship StrengthStudiesTrials
Depression, Endogenous
[description not available]		02.0410
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.4820
Depressive Disorder
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.		02.0410
Adipocere
[description not available]		02.2510
Electrocardiogram QT Prolonged
[description not available]		02.2510
Long QT Syndrome
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.		02.2510
Affective Psychosis, Bipolar
[description not available]		03.4820
Depression, Involutional
Form of depression in those MIDDLE AGE with feelings of ANXIETY.		02.5220
Bipolar Disorder
A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.		03.4820
Depressive Disorder, Major
Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)		02.5220
Dementia Praecox
[description not available]		03.8721
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		07.4820
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.		08.8721
Anhedonia
Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).		07.1110
Innate Inflammatory Response
[description not available]		02.1110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		07.1110
Psychoses
[description not available]		07.4620
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		07.0710
Psychotic Disorders
Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)		07.4620